Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
Displaying: 2,014 trials in your specialties ()
View trials across your selected specialties

A Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Ixazomib, Drug: Ixazomib Placebo

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Beijing Chaoyang Hospital Capital Medical University, Beijing, Beijing, China

Brief Summary

The purpose of this study is to determine the effect of ixazomib maintenance therapy on progression-free survival (PFS) compared with placebo, in participants in China with newly diagnosed multiple myeloma (NDMM) who have had a major response [complete response (CR), very good partial response (VGPR), or partial response (PR)] to initial therapy and who have not undergone stem-cell transplantation (SCT). This study is a China continuation of the global study C16021 (NCT02312258).

Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Iron Deficiency Anemia, Anemia
View Full Trial
INTERVENTION

Drug: Ferrous Sulfate 300Mg Tablet, Drug: Vitamin C 500Mg tablet

Eligibility
  • Ages: 16 Years and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Brief Summary

Iron deficiency anemia is a global health problem and the most common cause of anemia worldwide. Patients with iron deficiency (ID) and IDA can present with a multitude of symptoms including fatigue, restless legs syndrome and pica.Oral iron supplementation is associated with increasing hemoglobin in multiple studies in women, pregnant women and elderly patients.However, the optimal dose and frequency of oral iron supplementation for treatment remains unclear. The current proposed study attempts to address this gap in the literature.

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Progressive Multiple Sclerosis (PMS)
View Full Trial
INTERVENTION

Drug: Ocrelizumab

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

MS Center of California, Newport Beach, California, United States

Brief Summary

This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).

Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Chronic Inflammatory Demyelinating Polyradiculoneuropathy
View Full Trial
INTERVENTION

Biological: HYQVIA, Biological: 0.25% albumin placebo solution with rHuPH20, Biological: IGIV

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Barrow Neurological Institute, Phoenix, Arizona, United States

Brief Summary

This is a Phase III, prospective, multicenter study with two study parts (epochs) to evaluate the efficacy, safety, and tolerability of HYQVIA/HyQvia (IGI, 10% with recombinant human hyaluronidase (rHuPH20) administered subcutaneously) for maintenance therapy to prevent relapse (Epoch 1) and GAMMAGARD LIQUID/KIOVIG (immunoglobulin G intravenous (IGIV) 10% administered intravenously) for the treatment of CIDP (Epoch 2). This study will enroll adult subjects with a confirmed diagnosis of CIDP and who have remained on a stable dosing regimen (monthly equivalent dose of 0.4 to 2.4 g/kg body weight (BW) with a dosing interval of 2 to 6 weeks) of IGIV therapy for at least 3 months prior to screening. In this double-blind, placebo-controlled phase of the study (Epoch 1), eligible subjects will be randomized in a 1:1 ratio to receive either HYQVIA/HyQvia or 0.25% albumin placebo solution with rHuPH20 every two, three, or four weeks in a double-blind fashion for a period of 6 months or until relapse. Subjects who relapse during Epoch 1 will enter Epoch 2 to receive IGIV treatment for a period of 6 months.

Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Veno-occlusive Disease
View Full Trial
INTERVENTION

Drug: Defibrotide, Other: Best Supportive Care

Eligibility
  • Ages: 1 Month and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Children's Hospital of Alabama, Birmingham, Alabama, United States

Brief Summary

This study is to compare the efficacy and safety of defibrotide prophylaxis in addition to best supportive care versus best supportive care alone in the prevention of hepatic veno- occlusive disease (VOD) in adult and pediatric patients undergoing hematopoietic stem cell transplant who are at high risk or very high risk of developing VOD.

Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Neuroendocrine Tumors
View Full Trial
INTERVENTION

Drug: Surufatinib, Other: Placebo

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Peking Union Medical College Hospital, Beijing, Beijing, China

Brief Summary

A randomized, double-blind, placebo controlled, multi-center Phase III study to assess the efficacy of Surufatinib 300 mg once a day in treating advanced pancreatic neuroendocrine tumors.

Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Bipolar Depression
View Full Trial
INTERVENTION

Drug: ITI-007, Drug: Placebo

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Clinical Site, Rogers, Arkansas, United States

Brief Summary

The study will evaluate the efficacy and safety of ITI-007 adjunctive to lithium or valproate in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode.

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell ...
View Full Trial
INTERVENTION

Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody, Drug: Carboplatin, Drug: Cisplatin, Drug: Gemcitabine, Drug: Pemetrexed

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University of California San Diego, La Jolla, California, United States

Brief Summary

This randomized, open-label study will evaluate the efficacy and safety of atezolizumab compared with chemotherapy consisting of a platinum agent (cisplatin or carboplatin per investigator discretion) combined with either pemetrexed (non-squamous disease) or gemcitabine (squamous disease) in programmed death-ligand 1 (PD-L1)-selected, chemotherapy-naive participants with Stage IV Non-Squamous or Squamous NSCLC.

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Psoriasis
View Full Trial
INTERVENTION

Drug: Risankizumab, Device: Autoinjector

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

UAB Department of Dermatology /ID# 210384, Birmingham, Alabama, United States

Brief Summary

The objectives of this study are to evaluate the usability of the combination product of risankizumab in an autoinjector (AI), as well as to evaluate the efficacy, safety, and tolerability of risankizumab administered by AI for the treatment of participants with moderate to severe plaque psoriasis.

Confirmatory Study of BK1310 in Healthy Infants

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Pertussis, Poliomyelitis, Bacterial Meningitis, Tetanus, Diphtheria
View Full Trial
INTERVENTION

Biological: DPT-IPV-Hib, Biological: Hib vaccine, Biological: DPT-IPV

Eligibility
  • Ages: 2 to 42 Months (Child)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

Investigational Site, Fukuoka-shi, Fukuoka, Japan

Brief Summary

The purpose of this study is to evaluate immunogenicity of BK1310 for all antigens (anti-PRP, diphtheria toxin, pertussis, tetanus toxin, and polio virus), after 3 times of injection, when compared noninferiority with co-administration of ActHIB® and Tetrabik, as well as efficacy and safety, in healthy infants.